TIDMIMM

RNS Number : 8372M

Immupharma PLC

14 May 2020

RNS: FOR IMMEDIATE RELEASE 14 May 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

ImmuPharma's efforts in the fight against Covid-19 with Lupuzor(TM) and Ureka

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company provides a progress update on activities around Covid-19.

On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new 'Anti-Infective' programs, one of which was in 'Antivirals'. Investigation of the application of the Ureka peptide technologies within this Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies. Further exploratory work continues on this program.

As part of an overall evaluation of how we might apply our patented technologies to the fight against the Covid-19 epidemic, within our 'Autoimmunity' therapy area, we have also been considering the unique way that Lupuzor (TM) interacts with the immune system and any potential application to Covid-19.

In this respect we note the results* of a recent study conducted at Emory University Atlanta GA, suggesting that Covid-19 (SARS-COV-2) patients and systemic lupus erythematosus (SLE) patients experiencing flares might share similar inflammatory symptoms, underpinned by similar mechanisms (role of cytokines). Lupuzor (TM) is a modulator of the immune response and an anti-inflammatory agent, which has activity against SLE (lupus), an autoimmune disease, as well as against other inflammatory diseases. ImmuPharma, together with its US licencing partner, Avion Pharmaceuticals, will be progressing Lupuzor (TM) into a new optimised international Phase III trial this year in lupus patients.

*"Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extraordinary B cell activation" - https://doi.org/10.1101/2020.04.29.20083717 .

Given the findings of the Atlanta research group, we postulate that Lupuzor (TM) may help to reduce or perhaps prevent the occurrence of the cytokine storm seen in Covid-19 patients. Further exploratory work is ongoing to assess Lupuzor's (TM) possible potential and clinical program in Covid-19 patients.

Commenting on the announcement, Dimitri Dimitriou, CEO and Dr Robert Zimmer, President & CSO of ImmuPharma said: " As the Covid-19 pandemic has unfolded, ImmuPharma has been evaluating how it can best contribute its expertise and resources to help in the global response. Using our longstanding knowledge of peptide based technology, provides us with a number of opportunities, to help bring together a therapy that could be effective against the inflammation that causes the serious complications of Covid-19. We look forward to providing further updates when appropriate".

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 ("MAR").

 
 
   For further information please contact: 
    ImmuPharma PLC ( www.immupharma.com ) 
     Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
    Dimitri Dimitriou, Chief Executive Officer 
    Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
    SPARK Advisory Partners Limited (NOMAD) 
     Neil Baldwin                                  +44 (0) 203 36 8 8974 
 
     Stanford Capital Partners (Joint Broker) 
     Patrick Claridge, John Howes                   +44 (0) 203 815 8880 
 
     SI Capital (Joint Broker) 
     Nick Emerson                                   +44 (0) 1483 413500 
    4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
     Jean-Charles Snoy 
 
     Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
     Erik De Clippel 
 
     Backstage Communication 
     Olivier Duquaine                               +32 (0) 477 504 784 
     Gunther De Backer                              +32 (0) 475 903 909 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase III trial for Lupuzor(TM) and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com . ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDKKNBDKBKBQPD

(END) Dow Jones Newswires

May 14, 2020 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Immupharma Charts.